T-cell receptor complex recognizing peptide–MHC class I (TCR-pMHC-I)

The T-cell receptor (TCR) complex recognizing peptide–MHC class I (pMHC-I) is a multi-subunit transmembrane assembly essential for the adaptive immune response, primarily expressed on CD8+ cytotoxic T cells [1.1.2, 1.4.2]. It consists of a variable αβ heterodimer responsible for antigen specificity, non-covalently associated with invariant CD3 signaling subunits (gamma/epsilon, delta/epsilon, and zeta/zeta dimers) [1.1.3, 1.1.4]. This complex specifically recognizes 8–12 amino acid peptides presented by MHC class I molecules, a process fundamental to identifying and eliminating virally infected or malignant cells [1.2.1, 1.5.1]. In therapeutic contexts, the TCR complex is modulated by anti-CD3 antibodies to manage autoimmunity or organ rejection, and its specificity is harnessed in TCR-engineered T-cell (TCR-T) therapies to target cancer-specific pMHC complexes [1.2.2, 1.3.1]. Key challenges in targeting this complex include ensuring high specificity to avoid off-target cross-reactivity with self-peptides and addressing the requirement for specific HLA matching in patients [1.5.1, 1.5.3].

Other names

TCR-CD3 complexαβ T-cell receptor complexMHC class I-restricted T-cell receptorTCR-pMHC complex

Modulation of T-cell activation through direct binding to CD3 subunits or the engineering of TCR αβ chains to recognize specific peptide-MHC class I complexes for targeted cytotoxicity.